Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Expert Review of Pharmacoeconomics & Outcomes Research|January 4, 2024
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspectiveJorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, et al.Expert Review of Pharmacoeconomics & Outcomes Research|January 29, 2024
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environmentJorge Mestre-Ferrandiz, Marcin Czech, Josef S Smolen, et al.Vaccines|March 28, 2024
Improving Vaccine Assessment Pathways and Decision Making in the Polish Immunization ProgramMarcin Czech, Ewa Augustynowicz, Michał Byliniak, et al.Vaccines|September 28, 2023
Respiratory Syncytial Virus Infections in Polish Pediatric Patients from an Expert PerspectiveMaria K Borszewska-Kornacka, Agnieszka Mastalerz-Migas, Aneta Nitsch-Osuch, et al.Journal of Medical Economics|May 11, 2016
Cost of severe hypoglycaemia in nine European countriesMichał Jakubczyk, Izabela Lipka, Justyna Pawęska, et al.Frontiers in Pharmacology|May 30, 2019
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European CountriesKrzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trąbka, et al.Journal of Comparative Effectiveness Research|March 2, 2023
Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision makingBertalan Németh, Maria Kamusheva, Zornitsa Mitkova, et al.Frontiers in Public Health|May 14, 2023
Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessmentAntal Zemplényi, Konstantin Tachkov, Laszlo Balkanyi, et al.Drugs & Aging|March 6, 2026
Advancing Vaccination Strategies for Older Adults: Insights of the Adult Immunization Board MeetingMarco Del Riccio, Stefania Maggi, Katarzyna Wieczorowska-Tobis, et al.Kardiologia Polska|September 16, 2025
Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarctionPrzemysław Mitkowski, Maciej Sterliński, Marcin Czech, et al.Pageof 7